Results 21 – 30 of 46 for constipation (0.02 seconds)

AstraZeneca PLC third quarter and nine months results 2014

approval and positive CHMP opinion for opioid-induced constipation. CAZ-AVI (ceftazidime-avibactam): Positive Phase III data for intra-abdominal ...

US FDA Approves Seroquel XR For Add-On Treatment Of Major Depressive Disorder

300 mg 40%), fatigue (150 mg: 14%, 300 mg: 11%) and constipation (150 mg only: 11%). In addition, the adverse events seen with SEROQUEL XR in these ...

ZS-9 (sodium zirconium cyclosilicate) Phase III long-term safety and efficacy data presented at ASN Kidney Week 2017

peripheral edema, urinary tract infection, nausea, constipation, anemia and upper respiratory tract infection.2 Dr. Steven Fishbane, Hofstra Northwell ...

AstraZeneca and Targacept Form Global Collaboration and Licence Agreement for Late-Stage Investigational Product TC-5214 for the Treatment of Major Depressive Disorder

frequent adverse events were headache, dizziness and constipation. There was no clinically significant difference between the dose groups in ...

Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

asthenia (54%), alopecia (51%), neutropenia (42%), constipation (33%), thrombo-cytopenia (30%), diarrhoea (28%), vomiting (26%), peripheral neuropathy ...

PRO - Gastrointestinal

Abdominal pain, Indigestion, Diarrhoea and Constipation. The reliability and validity of the GSRS are well-documented, and norm values for a general ...

Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer

vomiting, alopecia, fatigue, anaemia, diarrhoea and constipation. Cases of drug-related interstitial lung disease and pneumonitis, including grade 5 ...

Positive Phase III results demonstrate efficacy of antibiotic medicine CAZ-AVI in complicated Urinary Tract Infections

commonly reported adverse events were headache, nausea, constipation and diarrhoea. No new safety concerns were identified upon review of the most ...

AstraZeneca announces two Lancet Oncology publications of Phase I dose-expansion results of trastuzumab deruxtecan in HER2-positive metastatic breast and gastric cancer

vomiting, alopecia, fatigue, anaemia, diarrhoea, and constipation. 50% of patients experienced an AE grade ≥3, and 19% percent had a serious AE, ...

Elecoglipron, an oral small molecule GLP-1 RA, moves to Phase III programme and unlocks next chapter in AstraZeneca’s cardiometabolic and kidney portfolio

compared to placebo respectively were nausea (55%, 20%), constipation (41%, 6%), diarrhoea (35%, 25%) and vomiting (29%, 5%). In SOLSTICE, the most ...

Previous 1 2 3 4 5 6 Next